Jared Beaumont, M.P.H.1, Theresa Cassidy, M.P.H.1, Taryn Dailey Govoni, M.P.H.1
Presented at International Conference on Opioids 2017
“Abuse and route of administration prevalence for tapentadol products within the NAVIPPRO® ASI-MV® surveillance system”
Post-market surveillance data indicate low abuse levels of tapentadol products, but research regarding the route of administration profile of tapentadol abusers is limited. Our analyses evaluated abuse and routes of administration of tapentadol within a sample of 270,695 adults assessed for substance abuse problems during January 2012 through September 2016.